HENRY SCHEIN INC (HSIC): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
HENRY SCHEIN INC (HSIC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K HENRY SCHEIN INC false 0001000228 0001000228 2026-07-27 2026-07-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event rep
How this was made
The 30-second read
Why it matters
The company states that two executive vice presidents will move into senior advisory roles effective Oct. 30, 2026, with severance-plan payments and benefits under the Executive Severance Plan.
Market read
Personnel transition disclosure with severance-plan eligibility, likely a low-to-moderate sentiment driver but not a direct fundamental catalyst in the provided text.
What to watch
The key trading variable is whether the attached Exhibit 99.1 includes additional context (succession plan, strategic priorities, or interim leadership), which is not present in the scraped text.
Background
This is an SEC Form 8-K (Item 5.02) reporting executive leadership transitions and related compensatory arrangements.
Ticker impact
Henry Schein discloses that COO Michael Ettinger and Chief Strategic Officer Mark Mlotek will transition to senior advisory roles effective Oct. 30, 2026.
Near-term reaction likely limited; any move should fade unless investors read it as operational underperformance or a broader strategy change.
The filing is an 8-K Item 5.02 describing role transitions and eligibility for executive severance benefits, without new financial guidance, deal terms, or operational metrics.
Market effects
Minimal direct read-through to the broader healthcare distribution sector because the disclosure is personnel and severance-plan related, not a contract or demand shock.
No clear regional market linkage beyond US-listed sentiment.
Limited global relevance; no international operations, acquisitions, or regulatory actions are described.
Counterpoint
Investors may overreact to the advisory-role language; it can reflect planned succession or board refresh rather than cost cutting or performance issues.
Key entities
- issuerHenry Schein, Inc.
US healthcare distribution company filing the 8-K about executive transitions and compensatory arrangements.
- executiveMichael S. Ettinger
Executive Vice President and Chief Operating Officer transitioning to a senior advisory role effective Oct. 30, 2026.
- executiveMark E. Mlotek
Executive Vice President and Chief Strategic Officer transitioning to a senior advisory role effective Oct. 30, 2026.
